Using MRI and tumor genetics to guide treatment for small kidney tumors
Targeted Decision Making In Renal Cell Carcinoma Relying on a Radiogenomics Translational Platform
IRCCS San Raffaele · NCT06868927
This project will test whether combining MRI images with tumor biopsy genetics and tissue mapping can help guide treatment choices for adults with small (≤4 cm) kidney tumors who are having surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS San Raffaele (other) |
| Locations | 1 site (Milan, Italia) |
| Trial ID | NCT06868927 on ClinicalTrials.gov |
What this trial studies
This observational translational project integrates standard histology, immunohistochemistry, spatial transcriptomics, and genomic profiling of surgical tumor samples with MRI-based radiomics to build a radiogenomics decision platform. Adults with renal masses up to 4 cm who are candidates for renal surgery and can undergo MRI will be enrolled. Imaging and molecular data will be correlated to search for markers that predict response to systemic therapies or ablative treatments. The aim is to link noninvasive imaging features to underlying tumor biology to improve future treatment decisions.
Who should consider this trial
Good fit: Adults over 18 with a renal mass up to 4 cm who are scheduled for surgery, can undergo MRI, and provide informed consent are the intended participants.
Not a fit: Patients who cannot have an MRI, who have larger or metastatic tumors, or who are not surgical candidates are unlikely to benefit from this project.
Why it matters
Potential benefit: If successful, this approach could help doctors choose more precise treatments for small kidney tumors using MRI plus molecular biopsy data, potentially avoiding unnecessary therapies.
How similar studies have performed: Similar radiogenomics and spatial transcriptomics approaches have shown promising early results in small series but remain exploratory and not yet widely validated.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Presence of a renal mass up to 4 cm * Adult \> 18 years * Candidate to renal surgery * Informed consent signed Exclusion Criteria: * Contraindication for MRI
Where this trial is running
Milan, Italia
- IRCCS Ospedale San Raffaele — Milan, Italia, Italy (RECRUITING)
Study contacts
- Study coordinator: Umberto Capitanio
- Email: caitanio.umberto@hsr.it
- Phone: 3492503788
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Renal Tumors